His novel interdisciplinary approach is based on a strategy called “Lethal Mutagenesis” or “Viral Decay Acceleration,” an attempt to use a cancer cell’s own mutation process to eradicate the disease. One resulting drug, manufactured by Koronis Pharmaceuticals, which Professor Essigmann helped to found, is currently in clinical trials.